Mark D. Tyson, II, M.D., M.P.H.

Mark D. Tyson II, M.D., is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes:

• Treatments for muscle invasive and nonmuscle invasive bladder cancer.
• Robotic, open, and single port cystectomy
• Ileal conduits and orthotopic neobladders
• Intravesical therapy for nonmuscle invasive bladder cancer
• Understanding and improving quality of life for patients with bladder cancer
• Blue light cystoscopy.

In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer:

• CXB-01 - A randomized cross-over study to evaluate patient preference and satisfaction with urine-based molecular testing versus cystoscopy for surveillance for nonmuscle invasive bladder cancer.
• Sunrise 3 - A phase III open-label, multi-center, randomized study evaluating the efficacy and safety of TAR-200 in combination with cetrelimab versus intravesical BCG in participants with BCG-naïve high-risk nonmuscle invasive bladder cancer
• BOND-003: A phase III study of CG0070 in patients with nonmuscle invasive bladder cancer unresponsive to BCG
• KEYNOTE-676 Cohort A and Cohort B: A phase III, randomized comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer that is either persistent or recurrent following BCG induction (Cohort A) or that is naïve to BCG treatment (Cohort B).
• PATOPSCO - A Phase IIIb open-label, single arm, multi-center US study of BCG administered in combination with Durvalumab in adult BCG-naïve, high-risk nonmuscle invasive bladder cancer participants.
• PIVOT-006 - A phase III randomized study of CG0070 versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer following transurethral resection of bladder tumor.
• EV-104 - A study of intravesical enfortumab vedotin for treatment of patients with nonmuscle invasive bladder cancer.
• TARA-002 - A phase 1b/2 dose expansion open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high grade nonmuscle invasive bladder cancer. 
• SWOG S1602: A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle invasive bladder cancer.
• TAR-200-103: A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
• UGN-102: A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.

Dr. Tyson also provides second opinions remotely for newly diagnosed bladder and testis cancers.